ライフサイエンスコーパス: subcutaneous immunotherapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 red to compare sublingual immunotherapy with subcutaneous immunotherapy.

2 -life practice and comparing sublingual with subcutaneous immunotherapy.

3 gic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatmen

4 s of the cost-effectiveness of sublingual vs subcutaneous immunotherapy and of the cost-effectiveness

5 Three years of continuous treatment with subcutaneous immunotherapy and sublingual immunotherapy

6 Sublingual immunotherapy and subcutaneous immunotherapy are effective in seasonal all

7 acotherapy for allergic rhinoconjunctivitis, subcutaneous immunotherapy as compared with pharmacother

8 xtracts provides an appealing alternative to subcutaneous immunotherapy for the treatment of allergic

9 ponse in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated th

10 In contrast, low-dose subcutaneous immunotherapy has not shown clinical benefi

11 b or Toll-like receptor agonists to standard subcutaneous immunotherapy has proved beneficial.

12 Whereas subcutaneous immunotherapy induced a systemic increase i

13 and monthly placebo injections), 36 received subcutaneous immunotherapy (monthly injections containin

14 fic immunotherapy is a viable alternative to subcutaneous immunotherapy particularly attractive for u

15 nical efficacy and safety of Phleum pratense subcutaneous immunotherapy (Phl-SCIT) in LAR.

16 suggested significant preventive effects of subcutaneous immunotherapy (RR, 0.54; 95% CI, 0.38-0.84)

17 Both subcutaneous immunotherapy (SCIT) and sublingual immunot

18 and IgG4 levels during the updosing phase of subcutaneous immunotherapy (SCIT) are biomarkers of the

19 Specific subcutaneous immunotherapy (SCIT) for seasonal rhinoconj

20 Subcutaneous immunotherapy (SCIT) had a short-term and s

21 Subcutaneous immunotherapy (SCIT) has been the gold stan

22 abel safety and biomarker study of cockroach subcutaneous immunotherapy (SCIT) in adults.

23 elivery of Ova using the clinically-approved subcutaneous immunotherapy (SCIT) route.

24 Subcutaneous immunotherapy (SCIT) traditionally includes

25 ned with a suboptimal course of grass pollen subcutaneous immunotherapy (SCIT) using the allergen-ind

26 ted that sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) would be considered co

27 r by comparing with other therapies, such as subcutaneous immunotherapy (SCIT), or other pharmacother

28 T by comparing with other therapies, such as subcutaneous immunotherapy (SCIT), or other pharmacother

29 r by comparing with other therapies, such as subcutaneous immunotherapy (SCIT), or other pharmacother

30 Subcutaneous immunotherapy (SCIT)-treated patients (n =

31 to circulation system as compared to current subcutaneous immunotherapy (SCIT).

32 In contrast to conventional PLA2 subcutaneous immunotherapy, the therapeutic administrati

33 Subcutaneous immunotherapy was included as a positive co

34 Subcutaneous immunotherapy was most frequently used (80%

35 Subcutaneous immunotherapy with depigmented polymerized

36 Subcutaneous immunotherapy with high-dose grass pollen w

37 e, double-blind, placebo-controlled trial of subcutaneous immunotherapy with mixed depigmented-polyme

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。